The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes
Open accessAbstract
Importance: Results of clinical trials suggest that canagliflozin, a sodium-glucose cotransporter 2 (SGLT-2) inhibitor for treating type 2 diabetes, may be associated with lower extremity amputation. Objective: To quantify the association between the use of oral medication for type 2 diabetes and 5 outcomes (lower extremity amputation, peripheral arterial disease, critical limb ischemia, osteomyelitis, and ulcer). Design, Setting, and Participants: A retrospective cohort study was conducted using Truven Health MarketScan Commercial Claims and Encounters data on new users between September 1, 2012, and September 30, 2015. The study focused on 2.0 million commercially insured individuals and used propensity score weighting to balance baseline differences among groups. Sensitivity analyses varied statistical models, assessed the effect of combining dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) agonists as a single referent group, adjusted for baseline use of older oral agents, and included people with baseline amputation. Exposures: New use of SGLT-2 inhibitors alone, DPP-4 inhibitors alone, GLP-1 agonists alone, or other antidiabetic agents (sulfonylurea, metformin hydrochloride, or thiazolidinediones). Main Outcomes and Measures: Foot and leg amputation, defined by validated International Classification of Diseases, Ninth Revision and Current Procedural Terminology codes. Results: Among 2.0 million potentially eligible individuals, a total of 953 906 (516 046 women and 437 860 men; mean [SD] age, 51.8 [10.9] years) were included in the final analyses, including 39 869 new users of SGLT-2 inhibitors (4.2%), 105 023 new users of DPP-4 inhibitors (11.0%), and 39 120 new users of GLP-1 agonists (4.1%). The median observation time ranged from 99 days for new users of GLP-1 agonists to 127 days for those using metformin, sulfonylureas, and thiazolidinediones, while the crude incident rates ranged from 4.90 per 10 000 person-years for those using metformin, sulfonylureas, and thiazolidinediones to 10.53 per 10 000 person-years for new users of SGLT-2 inhibitors. After propensity score weighting and adjustment for demographics, severity of diabetes, comorbidities, and medications, there was a nonstatistically significant increased risk of amputation associated with new use of SGLT-2 inhibitors compared with DPP-4 inhibitors (adjusted hazard ratio, 1.50; 95% CI, 0.85-2.67) and GLP-1 agonists (adjusted hazard ratio, 1.47; 95% CI, 0.64-3.36). New use of SGLT-2 inhibitors was statistically significantly associated with amputation compared with sulfonylureas, metformin, or thiazolidinediones (adjusted hazard ratio, 2.12; 95% CI, 1.19-3.77). These results persisted in sensitivity analyses. Conclusions and Relevance: Use of SGLT-2 inhibitors may be associated with increased risk of amputation compared with some oral treatments for type 2 diabetes. Further observational studies are needed with extended follow-up and larger sample sizes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Observational data have been inconclusive.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [114]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
The Robust Inference for the Cox Proportional Hazards Model
Lin, D. Y., & Wei, L. J. (1989) · Journal of the American Statistical Association · doi:10.1080/01621459.1989.10478874 · Cited by 2,695
Checking the Cox model with cumulative sums of martingale-based residuals
LIN, D. Y., WEI, L. J., & YING, Z. (1993) · Biometrika · doi:10.1093/biomet/80.3.557 · Cited by 1,432
Harder, V. S., Stuart, E. A., & Anthony, J. C. (2010) · Psychological Methods · doi:10.1037/a0019623 · Cited by 802
Kurth, T., Walker, A. M., Glynn, R. J., Chan, K. A., Gaziano, J. M., Berger, K., & Robins, J. M. (2005) · American Journal of Epidemiology · doi:10.1093/aje/kwj047 · Cited by 733
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Self-citationNeal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1237 · Cited by 233
Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?
Liu, J., Lee, T. W., & DeFronzo, R. A. (2012) · Diabetes · doi:10.2337/db12-0052 · Cited by 227
Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer
Casadaban, L. C., Rauscher, G. H., Aklilu, M., Villenes, D., Freels, S. A., & Maker, A. V. (2016) · Cancer · doi:10.1002/cncr.30181 · Cited by 152
Flagged first, then by citations
2 of the 28 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Chang, 2012, Validating the adapted Diabetes Complications Severity Index in claims data., Am J Manag Care, 18, 721
- Centers for Disease Control and Prevention, 2017, National Diabetes Statistics Report, 2017
Cited by
Sorted by citations
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.008 · Cited by 1,373
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Salvatore, T., Galiero, R., Caturano, A., Rinaldi, L., Martino, A. D., Albanese, G., Salvo, J. D., Epifani, R., Marfella, R., Docimo, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073651 · Cited by 279
Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia
Polonsky, T. S., & McDermott, M. M. (2021) · JAMA · doi:10.1001/jama.2021.2126 · Cited by 211
Lower extremity arterial disease in patients with diabetes: a contemporary narrative review
Nativel, M., Potier, L., Alexandre, L., Baillet‐Blanco, L., Ducasse, E., Velho, G., Marre, M., Roussel, R., Rigalleau, V., & Mohammedi, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0781-1 · Cited by 207
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 204
An update on the safety of SGLT2 inhibitors
Scheen, A. J. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1602116 · Cited by 184
Lega, I. C., Bronskill, S. E., Campitelli, M. A., Guan, J., Stall, N. M., Lam, K., McCarthy, L. M., Gruneir, A., & Rochon, P. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13820 · Cited by 166
Creager, M. A., Matsushita, K., Arya, S., Beckman, J. A., Duval, S., Goodney, P. P., Gutierrez, J. A. T., Kaufman, J. A., Joynt Maddox, K. E., Pollak, A. W., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000967 · Cited by 164
The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients
Lim, J., Kwon, S., Jeon, Y., Kim, Y., Kwon, H., Kim, D. K., Lee, H., Kim, Y.-L., Kim, C., Park, S.-H., et al. (2022) · Transplantation · doi:10.1097/tp.0000000000004228 · Cited by 131
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
McGill, J. B., & Subramanian, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.029 · Cited by 121
Heyward, J., Mansour, O., Olson, L., Singh, S., & Alexander, G. C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234065 · Cited by 112
Self-citationSodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103
A safety update on sodium glucose co-transporter 2 inhibitors
Fitchett, D. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13611 · Cited by 99
Pasternak, B., Ueda, P., Eliasson, B., Svensson, A., Franzén, S., Guðbjörnsdóttir, S., Hveem, K., Jonasson, C., Wintzell, V., Melbye, M., et al. (2019) · BMJ · doi:10.1136/bmj.l4772 · Cited by 100
Pelletier, R., Ng, K., Alkabbani, W., Labib, Y., Mourad, N., & Gamble, J. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098621989134 · Cited by 93
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
Garofalo, C., Borrelli, S., Liberti, M., Andreucci, M., Conte, G., Minutolo, R., Provenzano, M., & Nicola, L. D. (2019) · Medicina · doi:10.3390/medicina55060268 · Cited by 95
Management of diabetic foot ulcers and the challenging points: An endocrine view
Doğruel, H., Aydemir, M., & Balcı, M. K. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i1.27 · Cited by 95
Nreu, B., Dicembrini, I., Tinti, F., Sesti, G., Mannucci, E., & Monami, M. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.03.013 · Cited by 89
Chunxing, L., Liang, S., Gao, L., & Liu, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244689 · Cited by 85
Paul, S. K., Bhatt, D. L., & Montvida, O. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa956 · Cited by 82
Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease
Badjatiya, A., Merrill, P., Buse, J. B., Goodman, S. G., Katona, B. G., Iqbal, N., Pagidipati, N. J., Sattar, N. A., Holman, R. R., Hernandez, A. F., et al. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.119.008018 · Cited by 63
Elnaem, M. H., Rosley, N. F. F., Alhifany, A. A., Elrggal, M. E., & Cheema, E. U. (2020) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s257273 · Cited by 57
Huang, C., & Lee, J. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14159 · Cited by 57
Katsiki, N., Dimitriadis, G., Hahalis, G. N., Παπάνας, Ν., Tentolouris, N., Triposkiadis, F. K., Tsimihodimos, V., Tsioufis, C. P., Mikhailidis, D. P., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.008 · Cited by 52
Chewcharat, A., Prasitlumkum, N., Thongprayoon, C., Bathini, T. J., Medaura, J. A., Vallabhajosyula, S., & Cheungpasitporn, W. (2020) · Medical Sciences · doi:10.3390/medsci8040047 · Cited by 52
Ujjawal, A., Schreiber, B., & Verma, A. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221090001 · Cited by 53
Fralick, M., Kim, S. C., Schneeweiss, S., Everett, B. M., Glynn, R. J., & Patorno, E. (2020) · BMJ · doi:10.1136/bmj.m2812 · Cited by 63
Potier, L., Roussel, R., Velho, G., Saulnier, P., Bumbu, A., Matar, O., Schneider, F. M., Ragot, S., Marre, M., Mohammedi, K., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4835-z · Cited by 48
Lee, H., Chen, S., Liu, J., Li, P., Wu, L., Chang, S., Yeh, Y., Kuo, C.-T., Chan, Y., & See, L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01118-0 · Cited by 49
Anderson, J. E. (2020) · Diabetes Spectrum · doi:10.2337/ds19-0031 · Cited by 49
Goldman, A., Fishman, B., Twig, G., Raschi, E., Cukierman‐Yaffe, T., Moshkovits, Y., Pomerantz, A., Ben‐Zvi, I., Dankner, R. S., & Maor, E. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01743-5 · Cited by 42
Scheen, A. J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101325 · Cited by 40
Non-immunological complications following kidney transplantation
Cohen‐Bucay, A., Gordon, C. E., & Francis, J. M. (2019) · F1000Research · doi:10.12688/f1000research.16627.1 · Cited by 43
Caparrotta, T. M., Greenhalgh, A. M., Osinski, K., Gifford, R. M., Moser, S., Wild, S. H., Reynolds, R. M., Webb, D. J., & Colhoun, H. M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01004-2 · Cited by 40
Alkabbani, W., & Gamble, J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15178 · Cited by 39
Yu, O. H. Y., Dell’Aniello, S., Shah, B. R., Brunetti, V. C., Daigle, J.-M., Fralick, M., Douros, A., Hu, N., Alessi‐Severini, S., Fisher, A., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0267 · Cited by 42
Jones, L. K., Tilberry, S., Gregor, C. M., Yaeger, L., Hu, Y., Sturm, A. C., Seaton, T., Waltz, T. J., Rahm, A. K., Goldberg, A. C., et al. (2021) · Implementation Science · doi:10.1186/s13012-021-01108-0 · Cited by 40
Safety of Sodium-Glucose Co-Transporter 2 Inhibitors
McGill, J. B., & Subramanian, S. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.08.006 · Cited by 37
Miyashita, S., Kuno, T., Takagi, H., Sugiyama, T., Ando, T., Valentin, N., Shimada, Y. J., Kodaira, M., Numasawa, Y., Kanei, Y., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108136 · Cited by 37
Yang, J. Y., Wang, T., Pate, V., Gower, E. W., Crowley, M. J., Buse, J. B., & Stürmer, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13647 · Cited by 36
Careful use to minimize adverse events of oral antidiabetic medications in the elderly
Scheen, A. J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912735 · Cited by 34
Ma, L., Liu, Q., Jiang, Y., Zhao, H., Zhao, T., Cao, Y., Li, P., & Niu, W. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14187 · Cited by 33
Dedicator of Cytokinesis 5 Regulates Keratinocyte Function and Promotes Diabetic Wound Healing
Qu, H., Tian, M., Wang, Y., Tan, L., Huang, B., Zhang, L., Liu, X., Long, M., Zhang, R., Liao, X., et al. (2021) · Diabetes · doi:10.2337/db20-1008 · Cited by 32
Scheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101275 · Cited by 32
SGLT2 Inhibitors and Safety in Older Patients
Pollack, R. M., & Cahn, A. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.002 · Cited by 31
Wen, S., Nguyen, T., Gong, M., Yuan, X., Wang, C., Jin, J., & Zhou, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s312527 · Cited by 34
Werkman, N. C. C., Driessen, J. H. M., Stehouwer, C. D. A., Vestergaard, P., Schaper, N. C., van den Bergh, J. P., & Nielen, J. T. H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01897-2 · Cited by 29
Fralick, M., Colacci, M., Thiruchelvam, D., Gomes, T., & Redelmeier, D. A. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14300 · Cited by 27
Dzaye, O. D. A., Berning, P., Razavi, A. C., Adhikari, R., Jha, K. K., Nasir, K., Ayers, J. W., Mortensen, M. B., & Blaha, M. J. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.936651 · Cited by 26
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., Aylward, P. E., Dalby, A. J., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058103 · Cited by 31
SGLT-2 inhibitors in diabetes: a focus on renoprotection
Gonzalez, D. E., Foresto, R. D., & Ribeiro, A. B. (2020) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.66.s1.17 · Cited by 26
Hong, A. T., Luu, I. Y.-K., Lin, F., Shin, L., Hsu, C., Shih, C.-D., Armstrong, D. G., & Tan, T. (2025) · Diabetes Care · doi:10.2337/dc25-0292 · Cited by 30
Du, Y., Bai, L., Fan, B., Ding, H., Ding, H., Hou, L., Ma, H., Xing, N., & Wang, F. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.12.007 · Cited by 25
Sridhar, V. S., Rahman, H. U., & Cherney, D. Z. I. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13965 · Cited by 24
Dixon, D. L., Khaddage, S., Bhagat, S., Koenig, R. A., Salgado, T. M., & Baker, W. L. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.04.004 · Cited by 24
Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes
Potier, L., Roussel, R., Marre, M., Bjornstad, P., Cherney, D. Z., Boustany, R. E., Fumeron, F., Venteclef, N., Gautier, J., Hadjadj, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-1062 · Cited by 24
Zaccardi, F., Davies, M. J., & Khunti, K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13929 · Cited by 22
Skeik, N., Elejla, S. A., Sethi, A., Manunga, J. M., & Mirza, A. K. (2023) · Vascular Medicine · doi:10.1177/1358863x221143811 · Cited by 21
Lajara, R. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1670017 · Cited by 21
Canagliflozin and Amputation Risk: Evidence So Far
Papadokostaki, E., Rizos, E. C., Tigas, S. K., & Liberopoulos, E. N. (2019) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734619878090 · Cited by 21
Ji, A., Chen, W., Liu, C., Zhang, T., Shi, R., Wang, X., Xu, H., & Li, D. (2023) · Food & Function · doi:10.1039/d3fo01093g · Cited by 20
Li, C. X., Liu, T. T., Zhang, Q., Xie, Q., Geng, X. H., Man, C., Li, J. Y., Mao, X. Y., Qiao, Y., & Liu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1275060 · Cited by 19
Eckert, A. J., Zimny, S., Altmeier, M., Dugic, A., Gillessen, A., Bozkurt, L., Götz, G., Karges, W., Wosch, F. J., Kreß, S., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13531 · Cited by 21
Yang, C., Peng, Z., Chen, Y.-C., Ou, H., & Kuo, S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836365 · Cited by 19
Zhao, H., Yan, M., Li, Z., Zhong, M.-K., Zhou, J., 钟明康, & Qiu, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1110575 · Cited by 18
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Ospina, N. S., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16147 · Cited by 18
Chang, H., Chou, Y.-Y., Tang, W., Chang, G.-M., Hsieh, C., Singh, S., & Tung, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-86516-4 · Cited by 18
Self-citationHong, A. T., Lin, F., Luu, I. Y.-K., Shin, L., Han, S. M., Armstrong, D. G., & Tan, T. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112982 · Cited by 17
Yang, L., Gabriel, N., Hernandez, I., Winterstein, A. G., & Guo, J. (2021) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5206 · Cited by 17
Sridhar, V. S., Dubrofsky, L., Boulet, J., & Cherney, D. Z. I. (2020) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2020-0100 · Cited by 15
Biscetti, F., Cecchini, A. L., Rando, M. M., Nardella, E., Gasbarrini, A., Massetti, M., & Flex, A. (2021) · Atherosclerosis Plus · doi:10.1016/j.athplu.2021.10.003 · Cited by 14
Up and down waves of glycemic control and lower-extremity amputation in diabetes
Caruso, P., Scappaticcio, L., Maiorino, M. I., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01325-3 · Cited by 15
SGLT2 Inhibitors and Peripheral Vascular Events
Marchiori, E., Rodionov, R. N., Peters, F., Magnussen, C., Nordanstig, J., Gombert, A., Spanos, K. T., Jarzebska, N., & Behrendt, C. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.03.001 · Cited by 15
Diabetes: the place of new therapies
Dhatariya, K. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818807599 · Cited by 14
Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation
Werkman, N. C. C., Nielen, J. T. H., van den Bergh, J. P., Ejskjær, N., Røikjer, J., Schaper, N. C., Rossi, B., Klungel, O. H., Vestergaard, P., de Vries, F., et al. (2020) · Current Drug Safety · doi:10.2174/1574886315666200805103053 · Cited by 14
Eng, K., Zebardast, N., Boland, M. V., Lo, J., Swaminathan, S. S., Friedman, D. S., & Sheng‐Kai, K. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.10.029 · Cited by 13
Miceli, G., Basso, M. G., Pennacchio, A. R., Cocciola, E., Pintus, C., Cuffaro, M., Profita, M., Rizzo, G., Sferruzza, M., & Tuttolomondo, A. (2024) · Medicina · doi:10.3390/medicina60111796 · Cited by 13
Scheen, A. J. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100054 · Cited by 12
Monteiro‐Soares, M., Ribeiro‐Vaz, I., & Boyko, E. J. (2019) · Diabetologia · doi:10.1007/s00125-019-4861-x · Cited by 11
Qiu, M., Ding, L., Xu-bin, W., Wei, W., & Zhou, H. (2020) · Medicine · doi:10.1097/md.0000000000023489 · Cited by 11
Chronic Disease Medication Adherence After Initiation of Buprenorphine for Opioid Use Disorder
Chang, H., Daubresse, M., Saloner, B. K., & Alexander, G. C. (2019) · Medical Care · doi:10.1097/mlr.0000000000001165 · Cited by 10
Self-citationNashar, K., & Khalil, P. (2022) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s234282 · Cited by 10
Nani, A., Carrara, F., Paulesu, C. M. E., Fratte, C. D., Padroni, M., Enisci, S., Bilancio, M. C., Romio, M. S., Bertuzzi, F., & Pintaudi, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123958 · Cited by 10
Ma, N., Xu, N., Yin, D., Liu, W. W., Wu, M., & Cheng, X. (2020) · Medicine · doi:10.1097/md.0000000000020737 · Cited by 10
Wen, S., Yuan, Y., Li, Y., Xu, C., Chen, L., Ren, Y., Wang, C., He, Y., Li, X., Gong, M., et al. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01985-2 · Cited by 12
Alkabbani, W., Shah, B. R., Zongo, A., Eurich, D. T., Alsabbagh, M. W., & Gamble, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15241 · Cited by 11
Lowry, S. J., Kay, C. N., Marsom, E. N., Park, J., Poole, S. G., & Page, A. T. (2020) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1695 · Cited by 10
Kristensen, F., Christensen, D. H., Callaghan, B. C., Nielsen, J. S., Andersen, H., Sørensen, H. T., & Thomsen, R. W. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-01262 · Cited by 9
Zaghloul, N., Awaisu, A., Mahfouz, A., Alyafei, S., & Elewa, H. F. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-022-01464-x · Cited by 9
Lee, H., Chuang, C., Li, P., Yeh, Y., Chan, Y., & See, L. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-00982-6 · Cited by 8
Lin, Y., Lin, C.-H., Lin, Y., Huang, Y., Tai, A., Fu, S., & Lin, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.01.016 · Cited by 8
Effectiveness of sodium‐glucose co‐transporter‐2 inhibitors on ischaemic heart disease
Shen, Y., Zhou, J., Shi, L., Nauman, E., Katzmarzyk, P. T., Price‐Haywood, E. G., Horswell, R. L., Chu, S. T., Yang, S., Bazzano, A. N., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14025 · Cited by 8
Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis
Qiu, M., Ding, L., Zhang, M., & Zhou, H. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107803 · Cited by 8
Žerovnik, Š., Kos, M., & Locatelli, I. (2021) · Acta Diabetologica · doi:10.1007/s00592-021-01805-8 · Cited by 7
Lee, Y., Dong, Y., Yang, W., Wu, L., Lin, J., & Chang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869804 · Cited by 7
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes
Al-Bazz, D. Y., & Wilding, J. P. H. (2020) · Future Cardiology · doi:10.2217/fca-2019-0065 · Cited by 8
Hayes, K. N., Berry, S. D., Munshi, M. N., & Zullo, A. R. (2023) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18360 · Cited by 7
Chang, S., Yan, J., & Mu, L. (2025) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-025-09128-3 · Cited by 6
Handling time‐varying treatments in observational studies: A scoping review and recommendations
Xu, J., He, Q., Wang, M., Liu, M., Li, Q., Ren, Y., Yao, M., Li, G., Lu, K., Zou, K., et al. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12600 · Cited by 6
Metadata
- Authors
- Chang, H.-Y., Singh, S., Mansour, O., Baksh, S., & Alexander, G. C.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Alexander, G. Caleb
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2018-09-01
- Volume
- 178
- Issue
- 9
- Pages
- 1190
- ISSN
- 2168-6106 (ISSN-L)
- PMC
- PMC6142968
- OpenAlex
- W2886009800
- Cited by
- 163
- References
- 28
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 18 · 2023: 25 · 2022: 20 · 2021: 19 · 2020: 32 · 2019: 23 · 2018: 5
- FWCI
- 15.72
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Internal Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (T32HL139426)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetic Foot Ulcer Assessment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- SGLT2 inhibitors, canagliflozin, lower limb amputation, type 2 diabetes, DPP-4 inhibitors, GLP-1 receptor agonists, peripheral arterial disease, critical limb ischemia, osteomyelitis, foot ulcer, drug safety, commercially insured patients, propensity score weighting, metformin
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Amputation, Surgical, Blood Glucose, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Population Surveillance, Retrospective Studies, United States, Incidence, Lower Extremity, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors, Propensity Score, Peripheral Arterial Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
